ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2009
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a leading developer and manufacturer of medical equipment for sleep-disordered breathing and respiratory disorders. The reporting period covers the three months ended September 30, 2009. The company operates manufacturing facilities in Australia, Singapore, France, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Q1 FY2010 (Sep 30, 2009) | Q1 FY2009 (Sep 30, 2008) |
|---|---|---|
| Net Revenue | $246.99 million | $217.93 million |
| Gross Profit | $150.18 million | $127.13 million |
| Gross Margin | 60.8% | 58.3% |
| Net Income | $42.10 million | $28.03 million |
| Diluted EPS | $0.55 | $0.36 |
| Operating Cash Flow | $64.14 million | $67.91 million |
| Cash and Equivalents | $477.82 million | $302.07 million |
| Total Debt | $163.39 million | Filing text does not provide clear total debt for prior period |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 13% year-over-year, driven by higher unit sales of flow generators, masks, and accessories. Excluding unfavorable foreign currency impacts, revenue grew 16%.
- Profitability: Net income increased 50% to $42.1 million. Gross margin expanded to 60.8% due to manufacturing cost savings, favorable product mix, and the depreciation of the Australian dollar.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 8% to $76.8 million, primarily due to increased personnel and stock-based compensation. Research and development (R&D) expenses increased 4% to $17.9 million.
- Foreign Currency: Currency fluctuations negatively impacted reported revenue by approximately $5.3 million but contributed to lower reported expenses and higher gross margins.
- Unusual Items: The company recorded a $1.0 million donation to the ResMed Foundation and a $0.25 million impairment loss on a cost-method investment.
Outlook, Risks, and Management Commentary
- Acquisition: On October 1, 2009, ResMed acquired Laboratoires Narval SA for EUR 8 million in cash to add a mandibular repositioning device therapy to its portfolio.
- Share Repurchases: The company repurchased 0.8 million shares for $35.7 million during the quarter. Approximately 9.1 million shares remain available under the current repurchase program.
- Liquidity: Management expects to meet short-term liquidity needs through cash on hand, operating cash flows, and $13.7 million in undrawn credit facilities.
- Investment Liquidity Risk: The company holds $4.3 million in auction rate securities that may not be liquidatable at par value prior to June 29, 2010, due to market liquidity issues. Management does not anticipate this affecting operations.
- Legal Proceedings: Ongoing litigation includes a dispute with the University of Sydney regarding intellectual property and a tax audit of a German subsidiary. Management does not expect these to have a material adverse effect.
Investor Verification Checklist
- Verify the sustainability of the 60.8% gross margin given the impact of the Australian dollar's depreciation.
- Monitor the liquidity status of the $4.3 million auction rate securities and potential write-downs if they cannot be redeemed at par.
- Assess the integration and revenue contribution of the newly acquired Laboratoires Narval SA.
- Review the progress of the University of Sydney intellectual property litigation and the German tax audit.
- Confirm the company's ability to maintain debt covenants, specifically the minimum EBITDA requirements for its subsidiaries.